Gram Peptides sold unapproved injectable peptide drugs and bacteriostatic water online as new drugs, FDA says.
What happened
FDA reviewed Gram Peptides' website from January to March 2026 and found it offered Retatrutide, Tirzepatide, and Bacteriostatic Water for Injection for sale in the United States. FDA said the products are unapproved new drugs and that website claims showed they were intended for human use, despite "Research Use Only" statements.
What FDA found
Gram Peptides offered Retatrutide, Tirzepatide, and Bacteriostatic Water for Injection for sale in the United States without FDA-approved applications, making them unapproved new drugs.
Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)Introducing or delivering these unapproved new drugs into interstate commerce violates the FD&C Act.
Sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)The products are "new drugs" because they are not generally recognized as safe and effective for the uses described in their labeling.
Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)Website labeling showed the products were intended for human use as drugs, despite statements limiting them to research use.
21 CFR 201.128Bacteriostatic Water for Injection was sold alongside injectable peptide products, showing it was intended for use in injection.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
What FDA wants
FDA asks Gram Peptides to notify FDA in writing within 15 working days of receipt about the specific steps taken to correct the violations and prevent recurrence, including related documentation. If the company cannot complete corrections in that time, it must state why and when it will finish.
Who should pay attention
- online peptide and supplement sellers
- companies selling injectable research chemicals
- clinics or buyers sourcing peptides online
This is a summary. Read the original letter on fda.gov.